AC Immune S.A.ACIUNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank3
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P3
Near historical low
vs 5Y Ago
-1.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -22.32% |
| Q2 2025 | 5.72% |
| Q1 2025 | 0.83% |
| Q4 2024 | 9.00% |
| Q3 2024 | -15.50% |
| Q2 2024 | 13.01% |
| Q1 2024 | 3.56% |
| Q4 2023 | 18.03% |
| Q3 2023 | -9.32% |
| Q2 2023 | -1.38% |
| Q1 2023 | -8.34% |
| Q4 2022 | 5.22% |
| Q3 2022 | -8.33% |
| Q2 2022 | 3.76% |
| Q1 2022 | -24.85% |
| Q4 2021 | 33.11% |
| Q3 2021 | 10.27% |
| Q2 2021 | 2.86% |
| Q1 2021 | -16.44% |
| Q4 2020 | 2.79% |
| Q3 2020 | 21.15% |
| Q2 2020 | -15.78% |
| Q1 2020 | 3.73% |
| Q4 2019 | 27.74% |
| Q3 2019 | -9.62% |
| Q2 2019 | 9.56% |
| Q1 2019 | -4.41% |
| Q4 2018 | 5.03% |
| Q3 2018 | 9.62% |
| Q2 2018 | 4.61% |
| Q1 2018 | -0.85% |
| Q4 2017 | 23.92% |
| Q3 2017 | 19.84% |
| Q2 2017 | -8.26% |
| Q1 2017 | 5.58% |
| Q4 2016 | -8.26% |
| Q3 2016 | 36.31% |
| Q2 2016 | 5.10% |
| Q1 2016 | -5.80% |
| Q4 2015 | 37.22% |